NeuroOne to Present at H.C. Wainwright 23rd Annual Global Investment Conference
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced its participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference, taking place virtually from September 13-15, 2021. The presentation will be available on-demand starting September 13. Management will also conduct one-on-one investor meetings during the event. NeuroOne focuses on innovative surgical solutions for neurological disorders, having received FDA clearance for its Evo cortical and sEEG electrode technologies. The company aims to improve patient outcomes and reduce costs.
Details
News Market Reaction – NMTC
The recorded move for NMTC in the trading session of this news was -13.07%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EDEN PRAIRIE, Minn., Sept. 9, 2021 /PRNewswire/ -- NeuroOne® Medical Technologies Corporation (Nasdaq: NMTC) (NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today that management will present at the H.C. Wainwright 23rd Annual Global Investment being held virtually from September 13th to 15th, 2021.
- Date and Time: Presentation will be available on-demand beginning September 13, 2021.
- Webcast: https://journey.ct.events/view/5bcabc46-d156-4296-8d5b-18fed2162041
- Management will also host 1x1 investor meetings during the conference.
To learn more or to schedule a one-on-one meeting with management, please contact your conference representative or james@haydenir.com.
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information, visit https://www.n1mtc.com .
The Company previously announced it had successfully met the first performance milestone in the distribution and development agreement signed with Zimmer Biomet on July 20, 2020 . In addition to acquiring exclusive global distribution rights to NeuroOne's Evo® (Evo) patented electrode technology, the partnership also offered the potential for NeuroOne to earn back-end milestone payments if certain events were met within a specified time frame.
NeuroOne received FDA clearance for its Evo cortical technology in November 2019 and received FDA clearance for its Evo sEEG electrode technology (for 24-hour use) in September 2021.
In partnership with Mayo Clinic, Wisconsin Alumni Research Foundation (WARF) and other prominent academic medical centers, the Company began developing its cortical electrode technology in 2015. The Company initially focused its efforts on the epilepsy and intraoperative tumor monitoring markets. NeuroOne intends to continue to develop the technology for use in therapeutic applications for Parkinson's disease, epilepsy and pain management due to failed back surgery procedures.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neuroone-to-present-at-hc-wainwright-23rd-annual-global-investment-conference-301371980.html
SOURCE NeuroOne Medical Technologies Corporation
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.